Shen J - Search Results

1

miR-15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo.

Duan Z, Gao Y, Shen J, Choy E, Cote G, Harmon D, Bernstein K, Lozano-Calderon S, Mankin H, Hornicek FJ. Duan Z, et al. Among authors: shen j. Mol Oncol. 2017 Feb;11(2):151-166. doi: 10.1002/1878-0261.12015. Epub 2016 Oct 24. Mol Oncol. 2017. PMID: 28145098 Free PMC article. Clinical Trial.

2

Development of a new pre-vascularized tissue-engineered construct using pre-differentiated rADSCs, arteriovenous vascular bundle and porous nano-hydroxyapatide-polyamide 66 scaffold.

Yang P, Huang X, Shen J, Wang C, Dang X, Mankin H, Duan Z, Wang K. Yang P, et al. Among authors: shen j. BMC Musculoskelet Disord. 2013 Nov 8;14:318. doi: 10.1186/1471-2474-14-318. BMC Musculoskelet Disord. 2013. PMID: 24209783 Free PMC article.

3

Prognostic significance of miRNA-1 (miR-1) expression in patients with chordoma.

Duan Z, Shen J, Yang X, Yang P, Osaka E, Choy E, Cote G, Harmon D, Zhang Y, Nielsen GP, Spentzos D, Mankin H, Hornicek F. Duan Z, et al. Among authors: shen j. J Orthop Res. 2014 May;32(5):695-701. doi: 10.1002/jor.22589. Epub 2014 Feb 5. J Orthop Res. 2014. PMID: 24501096 Free PMC article.

4

MicroRNA-1 (miR-1) inhibits chordoma cell migration and invasion by targeting slug.

Osaka E, Yang X, Shen JK, Yang P, Feng Y, Mankin HJ, Hornicek FJ, Duan Z. Osaka E, et al. Among authors: shen jk. J Orthop Res. 2014 Aug;32(8):1075-82. doi: 10.1002/jor.22632. Epub 2014 Apr 24. J Orthop Res. 2014. PMID: 24760686 Free PMC article.

5

Programmed cell death ligand 1 expression in osteosarcoma.

Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Shen JK, et al. Cancer Immunol Res. 2014 Jul;2(7):690-698. doi: 10.1158/2326-6066.CIR-13-0224. Epub 2014 Apr 21. Cancer Immunol Res. 2014. PMID: 24866169 Free PMC article.

6

Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.

Choy E, MacConaill LE, Cote GM, Le LP, Shen JK, Nielsen GP, Iafrate AJ, Garraway LA, Hornicek FJ, Duan Z. Choy E, et al. Among authors: shen jk. PLoS One. 2014 Jul 1;9(7):e101283. doi: 10.1371/journal.pone.0101283. eCollection 2014. PLoS One. 2014. PMID: 24983247 Free PMC article.

7

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.

Duan Z, Zhang J, Ye S, Shen J, Choy E, Cote G, Harmon D, Mankin H, Hua Y, Zhang Y, Gray NS, Hornicek FJ. Duan Z, et al. Among authors: shen j. BMC Cancer. 2014 Sep 19;14:681. doi: 10.1186/1471-2407-14-681. BMC Cancer. 2014. PMID: 25236161 Free PMC article.

8

Targeting CDK11 in osteosarcoma cells using the CRISPR-Cas9 system.

Feng Y, Sassi S, Shen JK, Yang X, Gao Y, Osaka E, Zhang J, Yang S, Yang C, Mankin HJ, Hornicek FJ, Duan Z. Feng Y, et al. Among authors: shen jk. J Orthop Res. 2015 Feb;33(2):199-207. doi: 10.1002/jor.22745. Epub 2014 Oct 27. J Orthop Res. 2015. PMID: 25348612 Free PMC article.

9

Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential.

Shen JK, Cote GM, Choy E, Hornicek FJ, Duan Z. Shen JK, et al. Oncoimmunology. 2014 Aug 3;3(8):e954467. doi: 10.4161/21624011.2014.954467. eCollection 2014. Oncoimmunology. 2014. PMID: 25610746 Free PMC article.

10

Targeted cancer therapy; nanotechnology approaches for overcoming drug resistance.

Gao Y, Shen JK, Milane L, Hornicek FJ, Amiji MM, Duan Z. Gao Y, et al. Among authors: shen jk. Curr Med Chem. 2015;22(11):1335-47. doi: 10.2174/0929867322666150209151851. Curr Med Chem. 2015. PMID: 25666804 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

20,849 results

Search Page

Filters